Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.10/656
Título: Effectiveness and safety of levosimendan in clinical practice
Autor: Silva-Cardoso, J
Ferreira, J
Oliveira-Soares, A
Martins-de-Campos, J
Fonseca, C
Lousada, N
Ilídio-Moreira, J
Rabaçal, C
Damasceno, A
Amorim, S
Seabra-Gomes, R
Ferreira, R
Abreu-Lima, C
Palavras-chave: Insuficiência cardíaca
Levosimendam
Heart failure
Levosimendan
Data: 2009
Editora: Sociedade Portuguesa de Cardiologia
Citação: Rev Port Cardiol. 2009 Feb;28(2):143-54
Resumo: BACKGROUND: In previous randomized studies levosimendan improved hemodynamics and clinical course, with a still unclear effect on prognosis. There are, however, few data regarding its effects when used in daily practice. AIMS: We evaluated the clinical effectiveness and safety of levosimendan in the treatment of acute systolic heart failure (SHF) in daily practice conditions. METHODS: In this prospective, multicenter, nonrandomized trial, a continuous infusion of levosimendan (0.05 microg/kg/min-0.2 microg/kg/min) was administered for 24 hours. An optional loading dose of 12 microg/kg over 10 minutes was used. The primary combined endpoint of clinical effectiveness (as defined by a eight-variable clinical score) and safety (defined by the absence of serious adverse events) was assessed at 24 hours after the beginning of treatment; a second similar primary combined endpoint was assessed at 5 days. RESULTS: One hundred and twenty-nine consecutive patients requiring inotropes despite optimal oral background heart failure therapy were recruited. The primary endpoint was reached in 80.6% at 24 hours and in 79.7% at 5 days. During the six months before levosimendan the number of patient days of hospitalization for heart failure was 14.9 +/- 14.6 versus 3.1 +/- 7.6 during the six months following levosimendan (p < 0.001). CONCLUSIONS: In daily practice, levosimendan was clinically effective and safe in 80.6% and 79.7% of patients with acute SHF at 24 hours and 5 days respectively after the beginning of treatment. A marked reduction in the number of days of hospitalization for heart failure was also seen during the subsequent six months.
Peer review: yes
URI: http://hdl.handle.net/10400.10/656
ISSN: 0870-2551
Aparece nas colecções:CAR - Artigos

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Rev Port Cardiol 2009, 28 (2) 143-154.pdf299,05 kBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.